We use cookies to understand how you use our site and to improve your experience.
This includes personalizing content and advertising.
By pressing "Accept All" or closing out of this banner, you consent to the use of all cookies and similar technologies and the sharing of information they collect with third parties.
You can reject marketing cookies by pressing "Deny Optional," but we still use essential, performance, and functional cookies.
In addition, whether you "Accept All," Deny Optional," click the X or otherwise continue to use the site, you accept our Privacy Policy and Terms of Service, revised from time to time.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
Med tech clients scaled investments from 2022 to 2025, boosting adoption across brands and channels.
As life sciences companies increasingly shift toward targeted, AI-driven engagement, OptimizeRx (OPRX - Free Report) ’s ability to secure large enterprise deals and capitalize on med tech momentum could be decisive for its long-term growth trajectory.
Initial oncology pilots utilizing OptimizeRx’s point-of-care and prescribing solutions demonstrated strong results in reaching clinicians and influencing decisions within their workflows. As the DAAP model — its AI-driven platform enabling precise, timely engagement, including previously untapped prescribers — proved its value, a manufacturer expanded its investment in 2025 to support multiple oncology brands across various indications. This shift from pilot programs to a scaled, multi-brand strategy drove strong year-over-year growth, capturing the kind of enterprise momentum OptimizeRx is targeting.
OptimizeRx is also gaining significant traction in the med tech sector. A flagship client initially partnered post-COVID to expand prescriber reach through point-of-care marketing, with consistent script increases in 2024 leading to the adoption of DAAP. By activating these high-value HCP audiences, the client quickly scaled across brands and channels, creating meaningful impact in a competitive market. This success resulted in a sharp increase in investment from 2022 to 2025, demonstrating a recurring growth path from targeted POC engagement to DAAP-led, portfolio-wide expansion.
Per Market Reports World, the global MedTech market is projected to grow to $1,079.52 billion by 2034 at a CAGR of 4.87%. This creates a favorable macro backdrop for OPRX that enables digital engagement in healthcare. However, larger players in healthcare data and digital engagement, such as Doximity (DOCS - Free Report) and Veeva Systems (VEEV - Free Report) , pose significant competition.
Competitive Pressure Limiting OPRX’s Growth
Strong engagement and rapid AI adoption are driving Doximity's momentum, though delayed pharma spending and higher AI infrastructure costs remain near-term headwinds. Management expects a slow start to 2026 but anticipates a double-digit growth exit, supported by deferred budgets and AI commercialization. Ongoing AI investment and a solid balance sheet reinforce long-term confidence despite short-term uncertainties. Doximity continues investing in its doctor-trusted AI platform, spanning infrastructure, development and PeerCheck while expecting to sustain annual adjusted EBITDA margins of 50% or higher. It now expects fiscal 2026 revenue of $642.5–$643.5 million and adjusted EBITDA of $355.5–$356.5 million.
Veeva ended fiscal 2026 with record revenue and operating income, surpassing its $3B run-rate target and reaffirming plans for CRM to contribute roughly 10% of revenue by 2030. Ongoing innovation, strong customer trust and AI-driven product expansion in R&D and services support growth, while guidance signals confidence despite macro and migration risks. In March, Veeva acquired Ostro, an AI-driven engagement platform that delivers real-time, compliant answers to patients and doctors via brand websites. Using conversational AI and approved content, it provides trusted responses without hallucinations while generating insights to help life sciences companies improve reach and engagement.
OPRX Price Performance, Valuation & Estimates
Shares of OptimizeRx have lost 41.6% in the past three months compared with the Computer Software industry’s decline of 10.6%.
Image Source: Zacks Investment Research
Regarding the forward 12-month price/sales ratio, OPRX is trading at 1.11, lower than the industry’s multiple of 7.2.
Image Source: Zacks Investment Research
The Zacks Consensus Estimate for OPRX’s earnings for fiscal 2026 has been revised upward over the past 60 days.
View the Zacks #1 Rank List
Image: Bigstock
Will Enterprise Deals & MedTech Momentum Fuel OPRX's Growth Engine?
Key Takeaways
As life sciences companies increasingly shift toward targeted, AI-driven engagement, OptimizeRx (OPRX - Free Report) ’s ability to secure large enterprise deals and capitalize on med tech momentum could be decisive for its long-term growth trajectory.
Initial oncology pilots utilizing OptimizeRx’s point-of-care and prescribing solutions demonstrated strong results in reaching clinicians and influencing decisions within their workflows. As the DAAP model — its AI-driven platform enabling precise, timely engagement, including previously untapped prescribers — proved its value, a manufacturer expanded its investment in 2025 to support multiple oncology brands across various indications. This shift from pilot programs to a scaled, multi-brand strategy drove strong year-over-year growth, capturing the kind of enterprise momentum OptimizeRx is targeting.
OptimizeRx is also gaining significant traction in the med tech sector. A flagship client initially partnered post-COVID to expand prescriber reach through point-of-care marketing, with consistent script increases in 2024 leading to the adoption of DAAP. By activating these high-value HCP audiences, the client quickly scaled across brands and channels, creating meaningful impact in a competitive market. This success resulted in a sharp increase in investment from 2022 to 2025, demonstrating a recurring growth path from targeted POC engagement to DAAP-led, portfolio-wide expansion.
Per Market Reports World, the global MedTech market is projected to grow to $1,079.52 billion by 2034 at a CAGR of 4.87%. This creates a favorable macro backdrop for OPRX that enables digital engagement in healthcare. However, larger players in healthcare data and digital engagement, such as Doximity (DOCS - Free Report) and Veeva Systems (VEEV - Free Report) , pose significant competition.
Competitive Pressure Limiting OPRX’s Growth
Strong engagement and rapid AI adoption are driving Doximity's momentum, though delayed pharma spending and higher AI infrastructure costs remain near-term headwinds. Management expects a slow start to 2026 but anticipates a double-digit growth exit, supported by deferred budgets and AI commercialization. Ongoing AI investment and a solid balance sheet reinforce long-term confidence despite short-term uncertainties. Doximity continues investing in its doctor-trusted AI platform, spanning infrastructure, development and PeerCheck while expecting to sustain annual adjusted EBITDA margins of 50% or higher. It now expects fiscal 2026 revenue of $642.5–$643.5 million and adjusted EBITDA of $355.5–$356.5 million.
Veeva ended fiscal 2026 with record revenue and operating income, surpassing its $3B run-rate target and reaffirming plans for CRM to contribute roughly 10% of revenue by 2030. Ongoing innovation, strong customer trust and AI-driven product expansion in R&D and services support growth, while guidance signals confidence despite macro and migration risks. In March, Veeva acquired Ostro, an AI-driven engagement platform that delivers real-time, compliant answers to patients and doctors via brand websites. Using conversational AI and approved content, it provides trusted responses without hallucinations while generating insights to help life sciences companies improve reach and engagement.
OPRX Price Performance, Valuation & Estimates
Shares of OptimizeRx have lost 41.6% in the past three months compared with the Computer Software industry’s decline of 10.6%.
Image Source: Zacks Investment Research
Regarding the forward 12-month price/sales ratio, OPRX is trading at 1.11, lower than the industry’s multiple of 7.2.
Image Source: Zacks Investment Research
The Zacks Consensus Estimate for OPRX’s earnings for fiscal 2026 has been revised upward over the past 60 days.
Image Source: Zacks Investment Research
OPRX currently sports a Zacks Rank #1 (Strong Buy). You can see the complete list of today’s Zacks #1 Rank stocks here.